Putative roles of organic anion transporting polypeptides (OATPs) in cell survival and progression of human cancers

Biopharmaceutics and Drug Disposition

Volumn 35, Issue 8, 2014, Pages 463-484

  Nakanishi, Takeo ^a   Tamai, Ikumi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Breast cancer; Chemotherapy; Hormone refractory cancer; OATP; Prostate cancer; SLC transporter

Indexed keywords

ANTINEOPLASTIC AGENT; ORGANIC ANION TRANSPORTER; TUMOR PROTEIN;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CELL SURVIVAL; COLORECTAL CANCER; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; HEPG2 CELL LINE; HUMAN; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PATHOPHYSIOLOGY; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; DISEASE COURSE; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL SURVIVAL; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; ORGANIC ANION TRANSPORTERS;

EID: 84915803712     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1915     Document Type: Review

References (130)

1. Nakanishi T, Tamai I. Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. J Pharm Sci 2011; 100: 3731-3750. doi:10.1002/jps.22576
2. Okudaira H, Shikano N, Nishii R, et al. Putative transport mechanism and intracellular fate of trans-1-amino-3-18 F-fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med 2011; 52: 822-829. doi:10.2967/jnumed.110.086074
3. Fan X, Ross DD, Arakawa H, Ganapathy V, Tamai I, Nakanishi T. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors. Biochem Pharmacol 2010; 80: 811-818. doi:10.1016/j.bcp.2010.05.021
4. Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136: 521-534. doi:10.1016/j. cell.2008.11.044
5. Nakanishi T, Tamai I, Sai Y, Sasaki T, Tsuji A. Carrier- mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Cancer Res 1997; 57: 4118-4122
6. Nakanishi T, Tamai I, Takaki A, Tsuji A. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int J Cancer 2000; 88: 274-280. doi:10.1002/1097-0215(20001015)88:2274::aidijc20 3.0.co;2-5
7. Gonzalez DE, Covitz K-MY, SadeeW,Mrsny RJ. An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res 1998; 58: 519-525
8. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705. doi:10.1111/j.1476-5381.2009.00430.x
9. Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003; 23: 315-340. doi:10.1148/ rg.232025705
10. McConathy J, Goodman M. Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography. Cancer Metastasis Rev 2008; 27: 555-573. doi:10.1007/s10555-008-9154-7
11. Mitsuoka K, Miyoshi S, Kato Y, et al. Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter. J Nucl Med 2008; 49: 615-622. doi:10.2967/jnumed.107.048231
12. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009; 121: 29-40. doi:10.1016/j.pharmthera.2008.09.005
13. Jacquemin E, Hagenbuch B, Stieger B, Wolkoff AW, Meier PJ. Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc Natl Acad Sci U S A 1994; 91: 133-137
14. Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta Biomembr 2003; 1609: 1-18. doi:10.1016/S0005-2736(02)00633-8
15. Hagenbuch B,Meier PJ.Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004; V447: 653-665. doi:10.1007/s00424-003-1168-y
16. Nakanishi T, Tamai I. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab Pharmacokinet 2012; 27: 106-121. doi:10.2133/dmpk.DMPK-11-RV-099
17. König J. Uptake transporters of the human OATP family. In Drug Transporters, Fromm MF, Kim RB, König J (eds). Springer: Berlin, Heidelberg, 2011; 1-28
18. Sreedharan S, Stephansson O, Schioth HB, Fredriksson R. Long evolutionary conservation and considerable tissue specificity of several atypical solute carrier transporters. Gene 2011; 478: 11-18. doi:10.1016/j.gene.2010.10.011
19. Abe T, Kakyo M, Tokui T, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999; 274: 17159-17163. doi:10.1074/jbc.274.24.17159
20. Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). J Biol Chem 1999; 274: 37161-37168. doi:10.1074/jbc.274.52.37161
21. König J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000; 278: G156-G164
22. Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic anion-transporting polypeptide B (OATPB) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120: 525-533. doi:10.1053/gast.2001.21176
23. Maeda K, Ieiri I, Yasuda K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006; 79: 427-439. doi:10.1016/j.clpt.2006.01.011
24. Nakakariya M, Shimada T, Irokawa M, Maeda T, Tamai I. Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics. Drug Metab Pharmacokinet 2008; 23: 347-355. doi:10.2133/ dmpk.23.347
25. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010; 20: 112-120. doi:10.1097/FPC.0b013e328335b02d
26. Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 2008; 36: 663-669. doi:10.1124/dmd.107.017814
27. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005; 33: 434-439. doi:10.1124/dmd.104.001909
28. Takane H, Kawamoto K, Sasaki T, et al. Life-threatening toxicities in a patient with UGT1A16/28 and SLCO1B1 15/15 genotypes after irinotecanbased chemotherapy. Cancer Chemother Pharmacol 2009; 63: 1165-1169. doi:10.1007/s00280-008-0864-x
29. Wang X, Furukawa T, Nitanda T, et al. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol 2003; 63: 65-72
30. van de Steeg E, van der Kruijssen CMM, Wagenaar E, et al. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos 2009; 37: 277-281. doi:10.1124/dmd.108.024315
31. Katz DA, Carr R, Grimm DR, et al. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther 2006; 79: 186-196
32. Abe T, Unno M, Onogawa T, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001; 120: 1689-1699
33. König J, CuiY,NiesAT, KepplerD. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000; 275: 23161-23168. doi:10.1074/jbc.M001448200
34. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004; 311: 139-146. doi:10.1124/jpet.104.068056
35. Letschert K, Keppler D, König J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004; 14: 441-452
36. Hamada A, Sissung T, Price DK, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008; 14: 3312-3318. doi:10.1158/1078- 0432.ccr-07-4118
37. Ismair MG, Stieger B, Cattori V, et al. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology 2001; 121: 1185-1190
38. Tamai I, Nezu J-I, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000; 273: 251-260. doi:10.1006/bbrc.2000.2922
39. Kobayashi D, Nozawa T, Imai K, Nezu J-I, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 2003; 306: 703-708. doi:10.1124/jpet.103.051300
40. Gao B, Huber RD, Wenzel A, et al. Localization of organic anion transporting polypeptides in the rat and human ciliary body epithelium. Exp Eye Res 2005; 80: 61-72. doi:10.1016/j.exer.2004.08.013
41. Tamai I. Oral drug delivery utilizing intestinal OATP transporters. Adv Drug Deliv Rev 2012; 64: 508-514. doi:10.1016/j.addr.2011.07.007
42. Grube M, Kock K, Oswald S, et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 2006; 80: 607-620. doi:10.1016/j.clpt.2006.09.010
43. Kullak-Ublick GA, Hagenbuch B, Stieger B, et al. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 1995; 109: 1274-1282. doi:10.1016/0016-5085(95)90588-X
44. Mandery K, Bujok K, Schmidt I, et al. Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol 2010; 80: 1746-1753. doi:10.1016/j.bcp.2010.08.008
45. Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007; 81: 362-370. doi:10.1038/sj.clpt.6100056
46. Groer C, Bruck S, Lai Y, et al. LC-MS/MS-based quantification of clinically relevant intestinal uptake and efflux transporter proteins. J Pharm Biomed Anal 2013; 85: 253-261. doi:10.1016/j.jpba.2013.07.031
47. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic aniontransporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 2000; 294: 73-79
48. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol 2002; 16: 2283-2296. doi:10.1210/me.2001-0309
49. Lu R, Kanai N, Bao Y, Schuster VL. Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest 1996; 98: 1142-1149. doi:10.1172/JCI118897
50. Bao Y, Pucci ML, Chan BS, Lu R, Ito S, Schuster VL. Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids. Am J Physiol Renal Physiol 2002; 282: F1103-F1110. doi:10.1152/ajprenal.00152.2001
51. Nomura T, Lu R, Pucci ML, Schuster VL. The twostep model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Mol Pharmacol 2004; 65: 973-978. doi:10.1124/mol.65.4.973
52. Shirasaka Y, Shichiri M, Kasai T, et al. A role of prostaglandin transporter in regulating PGE2 release from human bronchial epithelial BEAS-2B cells in response to LPS. J Endocrinol 2013; 217: 265-274. doi:10.1530/JOE-12-0339
53. Schiffer R, Neis M, Holler D, et al. Active influx transport is mediated by members of the organic anion transporting polypeptide family in human epidermal keratinocytes. J Invest Dermatol 2003; 120: 285-291. doi:10.1046/j.1523-1747.2003.12031.x
54. Adachi H, Suzuki T, Abe M, et al. Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol 2003; 285: F1188-F1197. doi:10.1152/ajprenal.00402.2002
55. Huber RD, Gao B, Pfandler MS, et al. Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am J Physiol Cell Physiol 2007; 292: C795-C806. doi:10.1152/ajpcell.00597.2005
56. Fujiwara K, Adachi H, Nishio T, et al. Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology 2001; 142: 2005-2012. doi:10.1210/en.142.5.2005
57. Sato K, Sugawara J, Sato T, et al. Expression of organic anion transporting polypeptide E (OATP-E) in human placenta. Placenta 2003; 24: 144-148
58. cMikkaichi T, Suzuki T, Onogawa T, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A 2004; 101: 3569-3574. doi:10.1073/pnas.0304987101
59. Toyohara T, Suzuki T, Morimoto R, et al. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol 2009; 20: 2546-2555. doi:10.1681/ASN.2009070696
60. Okabe M, Szakacs G, Reimers MA, et al. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 2008; 7: 3081-3091. doi:10.1158/ 1535-7163.mct-08-0539
61. Iedauer R, Svoboda M, Wlcek K, et al. Different expression patterns of organic anion transporting polypeptides in osteosarcomas, bone metastases and aneurysmal bone cysts. Oncol Rep 2009; 22: 1485-1492
62. Wlcek K, Svoboda M, Sellner F, Krupitza G, Jaeger W, Thalhammer T. Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma. Cancer Biol Ther 2008; 7: 1450-1455
63. Olszewski-Hamilton U, Svoboda M, Thalhammer T, Buxhofer-Ausch V, Geissler K, Hamilton G. Organic anion transporting polypeptide 5A1 (OATP5A1) in small cell lung cancer (SCLC) cells: possible involvement in chemoresistance to satraplatin. Biomark Cancer 2011; 3: 31-40. doi:10.4137/BIC.S7151
64. Wlcek K, Svoboda M, Riha J, et al. The analysis of organic anion transporting polypeptide (OATP) mRNA and protein patterns in primary and metastatic liver cancer. Cancer Biol Ther 2011; 11: 801-811
65. Sebastian K, Detro-Dassen S, Rinis N, et al. Characterization of SLCO5A1/OATP5A1, a solute carrier transport protein with non-classical function. PLoS One 2013; 8: e83257. doi:10.1371/journal. pone.0083257
66. Suzuki T, Onogawa T, Asano N, et al. Identification and characterization of novel rat and human gonad-specific organic anion transporters. Mol Endocrinol 2003; 17: 1203-1215. doi:10.1210/ me.2002-0304
67. Lee SY,Williamson B, Caballero OL, et al. Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer. Cancer Immun 2004; 4: 13
68. Oba-Shinjo SM, Caballero OL, Jungbluth AA, et al. Cancer-testis (CT) antigen expression in medulloblastoma. Cancer Immun 2008; 8: 7
69. Reed MJ, Purohit A,Woo LWL, Newman SP, Potter BVL. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev 2005; 26: 171-202. doi:10.1210/er.2004-0003
70. Puranen T, Poutanen M, Ghosh D, Vihko P, Vihko R. Characterization of structural and functional properties of human 17 beta-hydroxysteroid dehydrogenase type 1 using recombinant enzymes and site-directed mutagenesis. Mol Endocrinol 1997; 11: 77-86
71. Miki Y, Nakata T, Suzuki T, et al. Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. J Clin Endocrinol Metab 2002; 87: 5760-5768
72. Ruder HJ, Loriaux L, Lipsett MB. Estrone sulfate: production rate and metabolism in man. J Clin Invest 1972; 51: 1020-1033. doi:10.1172/JCI106862
73. Utsumi T, Yoshimura N, Takeuchi S, Maruta M, Maeda K, Harada N. Elevated steroid sulfatase expression in breast cancers. J Steroid Biochem Mol Biol 2000; 73: 141-145
74. Miyoshi Y, Ando A, Hasegawa S, et al. High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptorpositive breast cancer. Clin Cancer Res 2003; 9: 2288-2293
75. Yoshimura N, Harada N, Bukholm I, Karesen R, Borresen-Dale AL, Kristensen VN. Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer. Breast Cancer Res 2004; 6: R46-R55. doi:10.1186/bcr746
76. Nozawa T, Suzuki M, Takahashi K, et al. Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells. J Pharmacol Exp Ther 2004; 311: 1032-1037. doi:10.1124/jpet.104.071522
77. Nozawa T, Suzuki M, Yabuuchi H, Irokawa M, Tsuji A, Tamai I. Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells. Pharm Res 2005; 22: 1634-1641. doi:10.1007/s11095-005- 7096-0
78. Miki Y, Suzuki T, Kitada K, et al. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res 2006; 66: 535-542. doi:10.1158/0008-5472. can-05-1070
79. Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB. Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res 2008; 68: 9338-9347. doi:10.1158/0008-5472.can-08-0265
80. Banerjee N, Allen C, Bendayan R. Differential role of organic anion-transporting polypeptides in estrone-3-sulphate uptake by breast epithelial cells and breast cancer cells. J Pharmacol Exp Ther 2012; 342: 510-519. doi:10.1124/jpet.112.192344
81. Pizzagalli F, Varga Z, Huber RD, Folkers G, Meier PJ, St-Pierre MV. Identification of steroid sulfate transport processes in the human mammary gland. J Clin Endocrinol Metab 2003; 88: 3902-3912. doi:10.1210/jc.2003-030174
82. Maeda T, Irokawa M, Arakawa H, et al. Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer. J Steroid Biochem Mol Biol 2010; 122: 180-185. doi:10.1016/j.jsbmb.2010.06.014
83. Banerjee N, Fonge H, Mikhail A, Reilly RM, Bendayan R, Allen C. Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. PLoS One 2013; 8: e64069. doi:10.1371/ journal.pone.0064069
84. Justenhoven C, Schaeffeler E, Winter S, et al. Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk. Breast Cancer Res Treat 2011; 125: 563-569. doi:10.1007/s10549- 010-1046-1
85. Al SW, Mokbel R, Salhab M, Jiang W, Reed M, Mokbel K. The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer. Anticancer Res 2006; 26: 4985-4990
86. Kindla J, Rau TT, Jung R, et al. Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue. Cancer Biol Ther 2011; 11: 584-591. DOI: 10.4161/cbt.11.6.14533
87. Muto M, Onogawa T, Suzuki T, et al. Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci 2007; 98: 1570-1576. doi:10.1111/j.1349-7006.2007.00570.x
88. Brawer MK. Hormonal therapy for prostate cancer. Rev Urol 2006; 8: S35-S47
89. Labrie F. Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol 2011; 8: 73-85. doi:10.1038/nrurol.2010.231
90. LeCluyse EL, Madan A, Hamilton G, Carroll K, DeHaan R, Parkinson A. Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2000; 14: 177-188. doi: 10.1002/(sici)1099-0461(2000)144177::aid-jbt13.0.co;2-4
91. Taplin M-E, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgenindependent prostate cancer.NEng JMed 1995; 332: 1393-1398. doi:10.1056/NEJM199505253322101
92. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45
93. Wright JL, Kwon EM, Ostrander EA, et al. Expression of SLCO transport genes in castrationresistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev 2011; 20: 619-627. doi:10.1158/1055-9965.epi-10-1023
94. Pressler H, Sissung TM, Venzon D, Price DK, Figg WD. Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One 2011; 6: e20372. doi:10.1371/journal.pone.0020372
95. Yang M, Xie W, Mostaghel E, et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2011; 29: 2565-2573. doi:10.1200/JCO.2010.31.2405
96. Kullak-Ublick G-A, Fisch T, Oswald M, et al. Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett 1998; 424: 173-176. doi:10.1016/ s0014-5793(98)00168-9
97. Cui Y, König J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001; 276: 9626-9630. doi:10.1074/jbc. M004968200
98. Labrie F, Bélanger A, Cusan L, Gomez J-L, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997; 82: 2396-2402. doi:10.1210/jc.82.8.2396
99. Arakawa H, Nakanishi T, Yanagihara C, et al. Enhanced expression of organic anion transporting polypeptides (OATPs) in androgen receptor-positive prostate cancer cells: possible role of OATP1A2 in adaptive cell growth under androgen-depleted conditions. Biochem Pharmacol 2012; 84: 1070-1077. doi:10.1016/j. bcp.2012.07.026
100. Longcope C. Metabolism of dehydroepiandrosterone. Ann N Y Acad Sci 1995; 774: 143-148. doi:10.1111/j.1749-6632.1995.tb17378.x
101. Muto M, Onogawa T, Suzuki T, et al. Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci 2007; 98: 1570-1576. doi:10.1111/j.1349-7006.2007.00570.x
102. LeeW, Belkhiri A, Lockhart AC, et al. Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res 2008; 68: 10315-10323. doi:10.1158/0008-5472.can-08-1984
103. Lockhart AC, Harris E, Lafleur BJ, et al. Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. Clin Exp Gastroenterol 2008; 1: 1-7
104. Smith NF, Acharya MR, Desai N, Figg W, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005; 4: 815-818
105. Yamaguchi H, Kobayashi M, Okada M, et al. Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett 2008; 260: 163-169
106. Baker SD, Verweij J, Cusatis GA, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2008; 85: 155-163
107. Ballestero MR, Monte MJ, Briz O, Jimenez F, Gonzalez-San Martin F, Marin JJ. Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem Pharmacol 2006; 72: 729-738. doi:10.1016/j.bcp.2006.06.007
108. Thakkar N, Kim K, Jang ER, et al. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm 2013; 10: 406-416. doi:10.1021/mp3005353
109. Han S, Kim K, Thakkar N, Kim D, Lee W. Role of hypoxia inducible factor-1alpha in the regulation of the cancer-specific variant of organic anion transporting polypeptide 1B3 (OATP1B3), in colon and pancreatic cancer. Biochem Pharmacol 2013; 86: 816-823. doi:10.1016/j.bcp.2013.07.020
110. Nagai M, Furihata T, Matsumoto S, et al. Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells. Biochem Biophys Res Commun 2012; 418: 818-823. doi:10.1016/j.bbrc.2012.01.115
111. Kleberg K, Jensen GM, Christensen DP, et al. Transporter function and cyclic AMP turnover in normal colonic mucosa from patients with and without colorectal neoplasia. BMC Gastroenterol 2012; 12: 78. doi:10.1186/1471-230X-12-78
112. Holla VR, Backlund MG, Yang P, Newman RA, DuBois RN. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (Phila) 2008; 1: 93-99. doi:10.1158/1940-6207. CAPR-07-0009
113. CuiY,Konig J,NiesAT, et al. Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab Invest 2003; 83: 527-538
114. Vavricka SR, Jung D, Fried M, Grutzner U, Meier PJ, Kullak-Ublick GA. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3b in hepatocellular carcinoma. J Hepatol 2004; 40: 212-218
115. Tsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging - correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010; 255: 824-833. doi:10.1148/ radiol.10091557
116. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44: 793-798. doi:10.1007/s00535-009-0056-4
117. Vasuri F, Golfieri R, Fiorentino M, et al. OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation. Virchows Arch 2011; 459: 141-146. doi:10.1007/ s00428-011-1099-5
118. Leonhardt M, Keiser M, Oswald S, et al. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 2010; 38: 1024-1028. doi:10.1124/dmd.110.032862
119. Kounnis V, Ioachim E, Svoboda M, et al. Expression of organic anion-transporting polypeptides 1B3, 1B1, and 1A2 in human pancreatic cancer reveals a new class of potential therapeutic targets. Onco Targets Ther 2011; 4: 27-32. doi:10.2147/ OTT.S16706
120. Hays A, Apte U, Hagenbuch B. Organic anion transporting polypeptides expressed in pancreatic cancer may serve as potential diagnostic markers and therapeutic targets for early stage adenocarcinomas. Pharm Res 2013; 30: 2260-2269. doi:10.1007/s11095-012-0962-7
121. Svoboda M, Wlcek K, Taferner B, et al. Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother 2011; 65: 417-426. doi:10.1016/j.biopha.2011.04.031
122. Bronger H, König J, Kopplow K, et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 2005; 65: 11419-11428. doi:10.1158/0008-5472.can-05-1271
123. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004; 76: 167-177
124. Nakagomi-Hagihara R, Nakai D, Kawai K, et al. OATP1B1, OATP1B3, and MRP2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos 2006; 34: 862-869. doi:10.1124/dmd.105.008888
125. Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006; 130: 1793-1806
126. Yamada A, Maeda K, Kamiyama E, et al. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1- receptor. Drug Metab Dispos 2007; 35: 2166-2176. doi:10.1124/dmd.107.017459
127. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002; 36: 164-172. doi:10.1053/jhep.2002.34133
128. Stute P, Reichenbach A, Szuwart T, Kiesel L, Gotte M. Impact of testosterone on the expression of organic anion transporting polypeptides (OATP-1A2, OATP-2B1, OATP-3A1) in malignant and non-malignant human breast cells in vitro. Maturitas 2012; 71: 376-384. doi:10.1016/ j.maturitas.2011.12.020
129. Nozawa T, Imai K, Nezu J-I, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 2004; 308: 438-445. doi:10.1124/jpet.103.060194
130. Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, Tamai I. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther 2010; 332: 181-189. doi:10.1124/jpet.109.159756